TapewireFind a company

person · Reporting owner

KIRSKE DAVID

Disclosed activity across 2 companies

Tapewire entity
33860
SEC CIK
0001276750

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
X4 Pharmaceuticals, IncXFOR · Entity 5638Chief Financial OfficerOctober 01, 2026October 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

X4 Pharmaceuticals, Inc

Report date October 01, 2026 · Filed October 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect155,983 Reported balance After 2026-10-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-10-01 · Sale · Disposed 11,767 · Balance 155,983

F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Of the shares of common stock reported, 64,418 shares represent restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Of the shares of common stock reported, 64,418 shares represent restricted stock units.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CTI BIOPHARMA CORP

Report date June 26, 2023 · Filed June 26, 2023

Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-06-26 transaction · row 1
1 source row

Row 1 · 2023-06-26 · Other · Disposed 17,547 · Balance 0

F1: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.

F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.25Direct0 Reported balance After 2023-06-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-06-26 · Disposition to issuer · Disposed 25,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19Direct0 Reported balance After 2023-06-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-06-26 · Disposition to issuer · Disposed 315,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14Direct0 Reported balance After 2023-06-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-06-26 · Disposition to issuer · Disposed 83,396 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95Direct0 Reported balance After 2023-06-26 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-06-26 · Disposition to issuer · Disposed 270,216 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00Direct0 Reported balance After 2023-06-26 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-06-26 · Disposition to issuer · Disposed 340,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30Direct0 Reported balance After 2023-06-26 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-06-26 · Disposition to issuer · Disposed 150,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49Direct0 Reported balance After 2023-06-26 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2023-06-26 · Disposition to issuer · Disposed 280,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55Direct0 Reported balance After 2023-06-26 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2023-06-26 · Disposition to issuer · Disposed 200,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.

F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 5, 2026 20:03 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 SaleCommon Stock 11,767 $2.86 $33,658.33
Disclosure

SEC source: 0001501697-26-000078 · wk-form4_1791230611.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,983

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 64,418 shares represent restricted stock units.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 20:23 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 SaleCommon Stock 8,543 $4.26 $36,428.21
Disclosure

SEC source: 0001501697-26-000065 · wk-form4_1782937402.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,750

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 96,627 shares represent restricted stock units.

Read SEC document
May 12, 2026 Filed May 13, 2026 20:02 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 SaleCommon Stock 16,961 $4.29 $72,820.36
Disclosure

SEC source: 0001501697-26-000049 · wk-form4_1778702561.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,293

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.20 to $4.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 128,836 shares represent restricted stock units.

Read SEC document
October 29, 2025 Filed Oct 31, 2025 20:41 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 GrantStock Option (right to buy) · Derivative 1,552,769 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001276750-25-000004 · wk-form4_1761943312.xml · derivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,552,769

Underlying: Common Stock · 1,552,769 shares

Expires 2035-08-12

F1 · derivative.exercise_date: Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

Read SEC document
August 14, 2025 Filed Aug 15, 2025 00:31 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 GrantStock Option (right to buy) · Derivative 352,800 $0.00 Strike: $3.14 $0.00
Disclosure

SEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · derivative · entry 3

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,800

Underlying: Common Stock · 352,800 shares

Expires 2035-08-14

F2 · derivative.exercise_date: One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026.

Read SEC document
August 14, 2025 Filed Aug 15, 2025 00:31 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 GrantCommon Stock 193,254 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,254

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive quarter thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.

Read SEC document
August 12, 2025 Filed Aug 15, 2025 00:31 UTC X4 Pharmaceuticals, Inc XFOR · Entity 5638 GrantStock Option (right to buy) · Derivative 1,073,249 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · derivative · entry 2

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,073,249

Underlying: Common Stock · 1,073,249 shares

Expires 2035-08-12

F2 · derivative.exercise_date: One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 200,000 Not disclosed Strike: $4.55 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 9

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 280,000 Not disclosed Strike: $4.49 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 8

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 280,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 150,000 Not disclosed Strike: $3.30 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 7

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 340,000 Not disclosed Strike: $1.00 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 6

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 340,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 270,216 Not disclosed Strike: $0.95 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 5

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 270,216 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 83,396 Not disclosed Strike: $4.14 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 4

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,396 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 315,000 Not disclosed Strike: $3.19 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 3

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 315,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $3.25 Not disclosed
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 2

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 OtherCommon Stock 17,547 $9.10 $159,677.70
Disclosure

SEC source: 0000899243-23-016485 · doc4.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.

F2 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Read SEC document
March 14, 2023 Filed Mar 16, 2023 17:52 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 GrantStock Option (right to buy) · Derivative 200,000 $0.00 Strike: $4.55 $0.00
Disclosure

SEC source: 0000899243-23-008752 · doc4.xml · derivative · entry 1

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-03-14

F1 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates.

Read SEC document
January 03, 2023 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 27,021 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 16

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,216

Underlying: Common Stock · 27,021 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
January 03, 2023 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 27,021 $6.01 $162,423.23
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 11

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,127

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Read SEC document
January 03, 2023 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 27,021 $0.95 $25,640.23
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 10

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,047 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 15

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,237

Underlying: Common Stock · 1,047 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 800 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 14

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,284

Underlying: Common Stock · 800 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 12,000 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 13

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,084

Underlying: Common Stock · 12,000 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 1,047 $6.01 $6,292.47
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 9

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,127

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 1,047 $0.95 $993.50
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 8

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,174

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 800 $6.01 $4,804.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 7

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,127

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 800 $0.95 $759.12
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 6

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 12,000 $6.00 $72,000.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 5

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,127

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 12,000 $0.95 $11,386.80
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 4

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Grantcommon stock 214 $5.11 $1,093.22
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 3

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,127

F2 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.

Read SEC document
December 29, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 13,174 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 12

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 311,084

Underlying: Common Stock · 13,174 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
December 29, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 13,174 $6.00 $79,044.00
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 2

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,913

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
December 29, 2022 Filed Jan 3, 2023 18:36 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 13,174 $0.95 $12,500.81
Disclosure

SEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 609 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · derivative · entry 9

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,258

Underlying: Common Stock · 609 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 100 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · derivative · entry 8

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,867

Underlying: Common Stock · 100 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,400 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · derivative · entry 7

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,967

Underlying: Common Stock · 1,400 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 609 $6.27 $3,818.43
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 6

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,913

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 609 $0.95 $577.88
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 5

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,522

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 100 $6.26 $626.00
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 4

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,913

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 100 $0.95 $94.89
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 3

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 1,400 $6.25 $8,750.00
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 2

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,913

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
October 04, 2022 Filed Oct 6, 2022 16:20 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 1,400 $0.95 $1,328.46
Disclosure

SEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 300 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 12

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,367

Underlying: Common Stock · 300 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 300 $6.25 $1,875.00
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 8

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,913

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 300 $0.95 $284.67
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 7

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 30, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 139,841 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 11

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,667

Underlying: Common Stock · 139,841 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
September 30, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Salecommon stock 139,841 $6.05 $845,548.61
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 6

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,913

F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Read SEC document
September 30, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversioncommon stock 139,841 $0.95 $132,695.12
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 5

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 29, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 100 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 10

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 466,508

Underlying: Common Stock · 100 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document
September 29, 2022 Filed Oct 3, 2022 18:26 UTC CTI BIOPHARMA CORP CTIC · Entity 111865 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 800 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 9

KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 466,608

Underlying: Common Stock · 800 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.